UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2013

CYTORI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34375	33-0827593
(State or Other Jurisdiction of Incorporation)	(Commission File	(I.R.S. Employer Identification Number)
	Number)	

3020 Callan Road, San Diego, California 92121

(Address of principal executive offices, with zip code)

(858) 458-0900

(Registrant's telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Dre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Dere-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On November 7, 2013 Cytori Therapeutics, Inc. (Company) issued a press release announcing its financial results for the third quarter ended September 30, 2013. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information disclosed under this Item 2.02 in this report, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Cytori Therapeutics, Inc. Press Release, dated November 7, 2013 *

* Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTORI THERAPEUTICS, INC.

By: /s/ Mark E. Saad Mark E. Saad Chief Financial Officer

Date: November 7, 2013



November 7, 2013

Cytori Reports Nine Month and Third Quarter 2013 Business and Financial Results

San Diego, CA - Cytori Therapeutics (NASDAQ: CYTX) today reports its nine month and third quarter 2013 financial results and provides updates on clinical development, commercialization and corporate development activities.

Total revenue for the nine months and quarter ended September 30, 2013 were \$8.7 million and \$2.7 million, respectively. Net loss for the nine months and quarter ended September 30, 2013 was \$16.1 million and \$5.3 million, respectively.

Milestone Highlights

Cytori's year-to-date accomplishments include the following:

- Formed a commercialization partnership for select emerging markets, including \$24 million in equity, a long term supply agreement with an initial \$7 million product purchase commitment, and up to \$500 million in commercial milestones
- Under the BARDA contract, the Company made significant progress toward the achievement of critical preclinical milestones needed to seek up to \$56 million in additional funding
- Expanded the number of actively recruiting centers in the ATHENA clinical trial program to seven and identified additional sites for ATHENA II
- · Received approvals for the Celution® System in Australia and Singapore
- Awarded seven patents, including a methods patent for using adipose-derived regenerative cell therapy for treating renal disease and licensed exclusive rights to a patent related to adipose-derived regenerative cells for the treatment of autoimmune diseases

"The recently signed partnership significantly strengthens our balance sheet, accelerates the expansion of our international cardiovascular business, and positions us for future revenue growth," said Christopher J. Calhoun, Cytori's Chief Executive Officer. "Year-to-date, we continued to make progress globally in our heart failure program and U.S. trials and are close to achieving all three objectives under the BARDA contract to qualify for the next phase worth up to \$56 million."

Financial Performance

Total revenues for the first nine months of 2013 were \$8.7 million compared to \$7.2 million for the first nine months of 2012. Total product and contract revenues for the first nine months of 2013 were \$6.9 million, which consisted of \$4.4 million in product sales and \$2.5 million in contract revenue. Total product and contract revenues for the first nine months of 2012 were \$4.8 million, which consisted of \$4.7 million in product sales and negligible contract revenues. Total product and cash contract revenues for the third quarter of 2013 were \$2.7 million, compared to \$1.3 million in the third quarter of 2012. Based on projected sales in the fourth quarter of 2013, Cytori reiterates its 2013 revenue objective of \$14 million in combined product and contract revenue.

Gross profit for the first nine months and quarter ended September 30, 2013 were \$2.1 million and \$0.7 million respectively compared to \$2.2 million and \$0.6 million respectively for the first nine months and quarter ended September 30, 2012.

Research and development expenses for the first nine months and quarter ended September 30, 2013 were \$12.0 million and \$4.1 million compared to \$9.6 million and \$3.6 million respectively for the first nine months and quarter ended September 30, 2012. The planned increase in research and development expenses is predominately related to reimbursed services performed under the BARDA contract, in addition to increased clinical trial costs. Sales, general and administrative expenses for the first nine months and quarter ended September 30, 2013 were \$18.7 million and \$6.1 million respectively compared to \$18.9 million and \$6.2 million respectively for the first nine months and quarter ended September 30, 2012.

Net loss for the first nine months of 2013 was \$16.1 million, or (\$0.24) per share, compared to \$28.5 million, or (\$0.49) per share, in the first nine months of 2012. Net loss for the third quarter of 2013 was \$5.3 million, or (\$0.08) per share, compared to \$11.2 million, or (\$0.19) per share, in the third quarter of 2012. The reduction of net loss for the first nine months of 2013 is predominately attributable to gains totaling \$9.3 million from the sale of Puregraft® in the third quarter of 2013 and from the gain on previously held equity interest in the Olympus-Cytori Joint Venture in the second quarter of 2013.

Cytori ended the third quarter of 2013 with \$10.2 million of cash and cash equivalents and \$2.6 million in accounts receivable. Subsequent to the end of the quarter, Cytori entered into a strategic partnership that will bring in \$24 million in committed capital before the end of the year from the partnering agreement. The cash is expected to enable the Company to meet potential 2014 milestones such as achieving options under the BARDA contract and presentation of initial ATHENA data.

Strategic Partnership

Emerging Markets

Cytori entered a partnership with Lorem Vascular subsequent to the end of the quarter to commercialize Cytori Cell Therapy in China, Hong Kong, Malaysia, Singapore and Australia. Under the agreement, Cytori and Lorem Vascular entered into a long term supply agreement for a 30-year exclusive license to Cytori Cell Therapy for cardiovascular disease, renal failure, diabetes, and all other indications, except alopecia and aesthetics, in the licensed territories. Pursuant to our agreement, Lorem Vascular will pay up to \$500 million in commercial milestones and will initially commit to order \$7 million in Celution® devices and consumables. Lorem Vascular will place its first order for \$2 million of Cytori Cell Therapy products immediately, followed by a \$5 million order to be placed upon regulatory approval in China, anticipated to be received in 2014. In a related transaction, Cytori will receive \$24 million in exchange for the sale of 8 million shares of Cytori common stock at \$3.00 per share. Equity purchased will be closed in two installments; a \$12 million payment has been received and a second \$12 million payment that will be made by the end of 2013. In addition, one board seat will be granted to Mr. K.T. Lim, Chairman of Lorem Vascular.

Cardiovascular Disease Pipeline

Heart Failure: ATHENA I & II Trials

ATHENA I is a prospective, multi-center, double-blind, randomized and placebo-controlled clinical trial investigating Cytori Cell Therapy for heart failure due to ischemic heart disease. ATHENA I will enroll 45 patients at a dose of 0.4MM cells/kg at eight centers. During the first quarter of 2014, the Company expects to initiate ATHENA II enrollment of 45 patients at a higher dose of 0.8MM cells/kg at up to ten trial centers. During the recent quarter, Cytori took action to modify the ATHENA protocols to enhance enrollment and safety, streamline the screening process, better align ATHENA I and II trials and facilitate the process of obtaining approval of an anticipated U.S. pivotal trial. Enrollment, which was deferred during the IRB approval process, has now resumed at seven of eight centers. Our updated projection is that ATHENA I should be fully enrolled by April 2014 and the first patient in ATHENA II may be enrolled in January 2014. Presentation of ATHENA I top-line six-month data is expected to be announced in the second half of 2014, full enrollment of ATHENA II is anticipated in the second half of 2014 and initiation of the U.S. pivotal trial in 2015.

Acute Myocardial Infarction: ADVANCE Trial

ADVANCE is the Company's European clinical trial for acute myocardial infarction (heart attacks). Cytori previously announced plans to discontinue ADVANCE following a review of the Company's global cardiovascular strategy, resource utilization and development priorities. The trial has enrolled 23 patients who will continue to be followed according to the trial protocol.

BARDA Contract

Cytori's contract with BARDA, a division of the U.S. Department of Health and Human Services, may provide up to \$106 million to fully fund the regulatory and clinical trials required by FDA to gain approval for Cytori's Celution® System for the treatment of thermal burn injuries. The initial phase of the contract includes approximately \$5 million in research funding to achieve three principal objectives. Attaining all three objectives qualifies Cytori to seek a second phase of the contract worth up to \$56 million in additional funding toward product development and clinical trials.

Cytori has submitted a final report demonstrating completion of the first objective, which was validation of the performance of the next-generation Celution® System. During the third quarter, Cytori submitted data to BARDA demonstrating substantial progress on the second and third objectives. On the basis of this progress the Company is in the process of accelerating the scheduling of an In-Process Review (IPR) meeting with BARDA early in the first quarter of 2014. Favorable review at this meeting may lead to funding of up to \$32.6 million over three years for Option 1. This would fund a pilot stage clinical trial program in thermal burn injury, ongoing development of the next generation Celution® System, and any FDA-required preclinical studies. Cytori anticipates a second IPR meeting on schedule for Option 3. Option 3 is valued at up to \$23.4 million over approximately four years.

Commercial Sales Efforts

Cytori's sales efforts continue to focus primarily on researchers performing investigator-initiated and sponsored studies. This supports the Company's strategy of facilitating the development of additional therapeutic applications for its cell therapy. For the fourth quarter of 2013 and into 2014, product revenue growth will be driven by expanded research and general clinical use based on recent regulatory approvals in Japan, Europe, and Asia Pacific, planned international registration studies, and the aforementioned strategic partnership.

Specifically, during the third quarter, Cytori received notice from the Australian Therapeutic Goods Administration (TGA) that the Celution® System was approved for commercial use through inclusion on the Australian Registry of Therapeutic Goods. Additionally, the Celution® System was approved subsequent to the end of the quarter in Singapore and Cytori has registered the Celution® System for commercial sale in New Zealand.

Upcoming Milestones

Cytori's key milestones for the next 12 months include the following:

- · Complete enrollment in the ATHENA I and II trials
- · Report six-month outcomes from the ATHENA trial
- · Achieve proof-of-concept milestones in the BARDA contract and qualify Cytori for up to \$56 million in additional development funding
- · Obtain product registration for the Celution® System in China
- · Achieve product and contract revenue objectives
- · Publish the long term outcomes from the PRECISE European chronic ischemic heart failure trial

Management Conference Call Webcast

Cytori will host a management conference call at 5:00 p.m. Eastern Time today to further discuss the Company's progress. The <u>webcast</u> will be available live and by replay two hours after the call and may be accessed under "Webcasts" in the <u>Investor Relations section</u> of Cytori's website. If you are unable to access the webcast, you may dial in to the call at +1-877-402-3914, Conference ID: 95080960.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position, such as our expectation of completion of enrollment of the ATHENA clinical trial by the end of the first quarter of 2014 with six month results in the second half of 2014, full enrollment in ATHENA II in 2014 and initiation of a pivotal trial in 2015, our ability to meet the BARDA proof-of-concept milestones by the first quarter of 2014 and conduct a successful In-Process Review meeting, our expectation of continuing demand from investigator-initiated trial customers, our expectation of product revenue growth based on recent regulatory approvals including Class I registrations in other regions throughout the world, our ability to meet our product and contract revenue objectives, our acceleration and expansion of our international cardiovascular business, and our publication of 18-month trial outcomes from the PRECISE trial. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include the level of future interest in our products by Japan research institutions, performance of our Japan distribution network, clinical, pre-clinical and regulatory uncertainties, such as those associated with the ATHENA clinical trial and the BARDA proof-of-concept milestones, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the "Risk Factors" in our annual and quarterly Securities and Exchange Commission Filings on Forms 10-K and 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Contact

Investor RelationsMediaTom BakerMegan McCormicktbaker@cytori.commmccormick@cytori.com+1.858.875.5258+1.858.875.5279

CYTORI THERAPEUTICS, INC. CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED)

	As of September 30, 2013		As of December 31, 2012	
Assets				
Current assets:				
Cash and cash equivalents	\$	10,205,000	\$	25,717,000
Accounts receivable, net of reserves of \$1,218,000 and of \$278,000 in 2013 and 2012, respectively		2,622,000		3,926,000
Inventories, net		4,138,000		3,175,000
Other current assets		1,128,000		1,161,000
Total current assets		18,093,000		33,979,000
Property and equipment, net of accumulated depreciation of \$9,131,000 and of \$8,609,000 in 2013 and 2012, respectively		1,550,000		2,174,000
Restricted cash and cash equivalents		350,000		350,000
Investment in joint venture				85,000
Other assets		1,962,000		2,740,000
Intangibles, net		9,345,000		
Goodwill		3,922,000		3,922,000
Tetel second	¢	25 222 000	¢	42.250.000
Total assets	\$	35,222,000	\$	43,250,000
Liabilities and Stockholders' Equity Current liabilities:				
Accounts payable and accrued expenses	\$	5,471,000	\$	7,411,000
Current portion of long-term obligations, net of discount	Ŷ	1,193,000	Ψ	9,784,000
Termination fee obligation		600,000		
Puregraft divestiture obligation		608,000		_
Joint Venture purchase obligation		4,772,000		
Warrant liability				418,000
Total current liabilities		12,644,000		17,613,000
Deferred revenues, related party		_		638,000
Deferred revenues		190,000		2,635,000
Option liability				2,250,000
Long-term deferred rent and other		754,000		756,000
Long-term obligations, net of discount, less current portion		24,822,000		12,903,000
Total liabilities		38,410,000		36,795,000
Commitments and contingencies Stockholders' equity:				
Preferred stock, \$0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2013 and 2012				_
Common stock, \$0.001 par value; 95,000,000 shares authorized; 67,270,466 and 65,914,050 shares issued and outstanding in 2013 and 2012, respectively		67,000		66,000
Additional paid-in capital		287,752,000		281,117,000
Accumulated other comprehensive loss		(142,000)		
Accumulated deficit		(290,865,000)		(274,728,000)
Total stockholders' (deficit) equity		(3,188,000)	_	6,455,000
Total liabilities and stockholders' equity	\$	35,222,000	\$	43,250,000

CYTORI THERAPEUTICS, INC. CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)

	For the Three Months Ended September 30,			For the Nine Months Ended September 30,				
		2013		2012	_	2013		2012
Product revenues	\$	1,616,000	\$	1,314,000	\$	4,416,000	\$	4,741,000
Cost of product revenues		931,000		703,000		2,296,000		2,588,000
Gross profit		685,000		611,000		2,120,000		2,153,000
Development revenues:								
Development, related party						638,000		2,413,000
Development revenue						1,179,000		_
Government contracts and other		1,095,000		2,000		2,503,000		21,000
		1,095,000	-	2,000		4,320,000	_	2,434,000
Operating expenses:	_	,,	-	,	-	,,	-	, - ,
Research and development		4,123,000		3,555,000		11,992,000		9,615,000
Sales and marketing		1,786,000		2,450,000		6,453,000		7,406,000
General and administrative		4,332,000		3,777,000		12,225,000		11,489,000
Change in fair value of warrant liability		4,332,000		863,000		(418,000)		1,244,000
Change in fair value of option liability				300,000		(2,250,000)		490,000
Change in fair value of option hability	_		_	500,000	-	(2,230,000)	_	430,000
Total operating expenses		10,241,000	_	10,945,000		28,002,000		30,244,000
Operating loss		(8,461,000)		(10,332,000)		(21,562,000)		(25,657,000)
Other income (expense):								
Loss on asset disposal		_		_		(257,000)		_
Loss on debt extinguishment						(708,000)		
Interest income		1,000				2,000		3,000
Interest expense		(1,094,000)		(857,000)		(2,456,000)		(2,582,000)
Other income (expense), net		(96,000)		(17,000)		(392,000)		(91,000)
Gain on Puregraft divestiture		4,392,000		(17,000)		4,392,000		(51,000)
Gain on previously held equity interest in Joint Venture		.,		_		4,892,000		_
Equity loss from investment in joint venture		_		(42,000)		(48,000)		(128,000)
1.5 5	_		_		-		_	
Total other income (expense)		3,203,000		(916,000)		5,425,000		(2,798,000)
Net loss	\$	(5,258,000)	\$	(11,248,000)	\$	(16,137,000)	\$	(28,455,000)
Other comprehensive income (loss) – foreign currency translation adjustments		(108,000)				(142,000)		
Net comprehensive loss	\$	(5,366,000)	\$	(11,248,000)	\$	(16,279,000)	\$	(28,455,000)
Basic and diluted net loss per common share	\$	(0.08)	\$	(0.19)	\$	(0.24)	\$	(0.49)
			_		_		_	
Basic and diluted weighted average common shares		67,248,384	_	58,713,036	_	67,147,584		58,292,911

CYTORI THERAPEUTICS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

Cash flows from operating activities: 2013 2012 Net loss \$ (16,137,000) \$ (26,455,000) Adjustments to reconcile net loss to net cash used in operating activities: 1,169,000 712,000 Depreciation and amorization 204,000 - Amorization obligation accretion 933,000 99,000 Okange in fair value of warrants 204,000 - Provision for doubtful account in value of warrants (212,000) - Gain on prevision for doubtful account in value of warrants (212,000) - Gain on prevision for doubtful account in value of warrants (212,000) - Gain on prevision for doubtful accounts 708,000 - Ions on beit of assets (24,902,000) - Increases (docrases) in tach caused by changes in operating assets and labilities: - - Increases (docrases) in tach caused by changes in operating activities - - Other creat assets (1,000,000) - - Increases of provins for doubtful accounts receivable - - - Other creat assets (1,000,000) -			For the Nine Months Ended September 30,		
Net Loss \$ (16,137,000) \$ (28,455,000) Adjustments to reconcile net loss to net cash used in operating activities: 1,169,000 712,000 Depreciation and amortization 605,000 706,000 Joint Venture acquisition obligation accretion 294,000 - Provision for doubdul accounts 993,000 (418,000) 1,244,000 Change in fair value of warrants (22,20,000) 400,000 - Gain on previously held equity interest in Joint Venture (43,8000) 1,224,000 - Cain on previously held equity interest in Joint Venture (43,900) - - Cain on previously held equity interest in Joint Venture (43,900) - - Cain on previously held equity interest in Joint Venture (43,900) - - Cain on previously held equity interest in Joint Venture (63,000) - - Increases (decreases) in cash caused by changes in operating assets and liabilities: - - - Accounts reviewable (53,000) (63,000) - - - Other accurent assets (67,000) - <t< th=""><th></th><th>2013</th><th>2012</th></t<>		2013	2012		
Adjustments to reconcile ner loss to net cash used in operating activities: Depreciation and amortization of deferred financing costs and debt discount Depreciation and amortization of deferred financing costs and debt discount Detro Values equipation accretion Provision for doubtil accounts Change in fair value of option liabilities Change in fair value of option liabilities Distar-based compensation expenses 2,723,000 2,907,000 Equip value of warrants C(1482,000) 1.244,000 Change in fair value of option liabilities 2,723,000 Equip value of warrants C(1482,000) 1.244,000 Change in fair value of option liabilities 2,723,000 Equip value of warrants C(1482,000) Casin on previously held equip interest in Joint Venture Casin on stel of assets (4.482,000) Loss on addet exitinguishment Cost on addet exitinguishment Encroses (dicetases) in cash caused by changes in operating assets and liabilities: 361,000 (253,000) Cost on asset (1120,000) (253,000) Cost on asset (1120,000) (253,000) Cost on asset (1120,000) (253,000) Cost on asset (1120,000) (253,000) Deferred revenues, equipment Accounts payable and accruad expenses (1127,000) (16,000 Cash Obos from investing activities 2000 Proceeds from severation equipment Net cash used in operating activities 2010 Net cash used in operating activities 2010 Net cash provided by (used in) investing activities 2010 Net cash provided by financing activities 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2	Cash flows from operating activities:				
Depreciation and amortization1.169.000712.000Amortization obligation accretion204.000Dirit Venture acquisition obligation accretion99.000Change in fair value of volumits99.000Change in fair value of volumits(2250.000)Optimity Park Tradue of volumits(2250.000)Share-based compensation expense(273.000)Putty loss form investment in joint venture(289.000)Cas on asset disposal(273.000)Cas on asset disposal(273.000)Cas on asset disposal(273.000)Cas on asset disposal(273.000)Cas on asset disposal(289.000)Cas on asset disposal(289.000)Cas on asset disposal(297.000)Cas on asset disposal(297.000)Cas on asset disposal(297.000)Cos on debt exitinguishment(361.000)Intervesses (faccuases) in cash caused by changes in operating assets and liabilities: Accounts payable and accrued expenses(117.000)Cos on debt exitinguishment(25.000.000)Other current assets(117.000)Deferred revenaes.(117.000)Deferred revenaes.(108.000)Cash flows from investing activities(25.000.000)Purchases of property and equipment(33.000)Deceeds from long exit obligations(22.92.000)Net cash provided by (used in) investing activities(21.000)Cash flows from investing activities(21.000.000)Principal apprents on long-term obligations(22.92.000)Cash acquired	Net loss	\$ (16,137,000) \$	6 (28,455,000)		
Anontzation of deferred financing costs and debt discount 605,000 706,000 Othm Venture equisition obligation accretion 938,000 99,000 Change in fair value of option liabilities (2,250,000) 490,000 Change in fair value of option liabilities (2,250,000) 490,000 Figure Value of warrants (2,250,000) 490,000 Class on asset disposal (2,723,000 2,907,000 Figure Value of warrants (4,892,000) Gain on previously held equity interest in Joint Venure (4,892,000) Cass on asset disposal (75,000) Increases (factor cassed by changes in operating assets and liabilities: 361,000 698,000 Increases (factor cassed by changes in operating assets and liabilities: 361,000 (23,000) Increases (factor cassed by changes in operating assets and liabilities: 361,000 (23,000) Other current assets (1,000,000) (23,000) (23,000) Other current assets (1,000,000) (23,000) (23,000) Deferred revenues, related party (53,000) (23,000) (24,000)	Adjustments to reconcile net loss to net cash used in operating activities:				
Joint Venture acquisition obligation accretion	Depreciation and amortization	1,169,000	712,000		
Provision for doubtful accounts 938,000 999,000 Change in fair value of option liabilities (248,000) 1,244,000 Change in fair value of option liabilities (2,250,000) 490,000 Bare-based compension expense 2,723,000 Gain on previously held equity interest in Joint Venture (4,832,000) Gain on set of asset (4,392,000) Caso on det cramguishment 700,000 Increases (decreases) in cash caused by changes in operating assets and liabilities: 361,000 698,000 Accounts receivable 636,000 (253,000) Chare a fair fair of the eventure states (630,000) (233,000) (244,000) Other current assets (11,7000) 16,000 (254,000) Accounts payable and accured expenses (11,70,000) 16,000 (244,000) (244,000) Deferred revenues, related party (638,000) (244,000) (23,007,000) Net cash used in operating activities (25,064,000) (23,077,000) Rows from investing activities (23,007,000) Decelered revenues, agreement termination fee (600,	Amortization of deferred financing costs and debt discount	605,000	706,000		
Change in fair value of sortantis (418,000) 12,444,000 Change in fair value of potton liabilities (2,250,000) 490,000 Equity loss from investment in joint venture 44,000 128,000 Loss on asset disposal 2270,000 Gain on previously held equity interest in Joint Venture (4,392,000) Loss on delt exitinguishment 700,000 Increases (fdecreases) in cash caused by changes in operating assets and liabilities: Accounts receivable (975,000) (935,000) Inventories (90,000 (935,000) Other current assets (1,176,000) 156,000 (743,000) Other current assets (1,245,000) (23,807,000) Deferrent revenues, related party (638,000) (2,413,000) Deferrent revenues (1,245,000) (1,077,000) Net cash used in operating activities Deferrent revenues, related party (536,000) (Loress acquired ret (Deferrent re	Joint Venture acquisition obligation accretion	204,000			
Change in fair value of option labilities(2,250,000)490,000Equity loss from investment in joint venture2,723,000Case na set disposal2,723,000Gain on previously bid equity interest in Joint Venture(4,382,000)Casin on set of asets(4,392,000)Case na set disposal708,000Case on set of asets(4,392,000)Case on set of asets(4,392,000)Case on set of asets(4,392,000)Case on set of asets(4,392,000)Case on set of asets(36,000)(393,000)Increases (decreases) in cash caused by changes in operating assets and liabilities:Accounts receivable(638,000)(233,000)Other current assets(11,70,000)166,000Accounts payable and accrued expenses(11,70,000)166,000Accounts payable and accrued expenses(11,245,000)(23,877,000)Net cash used in operating activities(23,877,000)(23,877,000)Cash flows from investing activities:Purchases of property and equipment(536,000)Net cash provided by (used in) investing activities(22,2000)(210,000)Cash acquired in purchase of foint Wenture5,000Net cash provided by (used in) investing activities(22,220,000)(210,000)Proceeds from functional curve5,000Net cash provided by (used in) investing activities(27,000,000)<	Provision for doubtful accounts	938,000	99,000		
Share-based compensation expense 2,723,000 2,907,000 Equity loss rom investment in joint venture 48,000 128,000 Casin on previously held equity interest in Joint Venture (4,492,000) Gain on previously held equity interest in Joint Venture (4,492,000) Casin on steed of assets (4,392,000) Increases (feetraces) in cash caused by changes in operating assets and liabilities: 708,000 Increases (feetraces) in cash caused by changes in operating assets and liabilities: 361,000 698,000 Inventories (9,75,000) (93,000) Other current assets 69,000 (23,000) Other current assets (1,080,000) 254,000 (24,3000) Deferred revenues, related party (638,000) (24,30,000) 180,000 Increase (denoted entry (22,000) 180,000 180,000 License agreement termination fee (600,000) Cash flows from investing activities Cash acquired in purchase of Joint Venture 5,000	Change in fair value of warrants	(418,000)	1,244,000		
Equity loss from investment in joint venture 44.000 128.000 Gain on previously held equity interest in Joint Venture (4.492,000) Gain on sale of assets (4.392,000) Casin on sale of assets (4.392,000) Increases (decreases) in cash caused by changes in operating assets and liabilities: 708,000 Accounts receivable 66,000 (253,000) 0.000 Other assets (10,000) 254,000 (253,000) Other assets (117,000) 16,000 254,000 Accounts requisable and accrued expenses (1,120,000) 254,000 (2413,000) Deferred revenues, related party (538,000) (24,000) 100,000 Net cash used in operating activities (20,000) 100,000 Cash flows from investing activities (360,000) (-24,87,000) Verchases of property and equipment (536,000) Purchases of property and equipment fee (600,000) Cash flows from financing activities: 3,869,000 (Change in fair value of option liabilities	(2,250,000)	490,000		
Loss on asset disposal 257,000	Share-based compensation expense	2,723,000	2,907,000		
Loss on asset disposal 257,000	Equity loss from investment in joint venture	48,000	128,000		
Gain on previously held equity interest in Joint Venture (4.392,000) Loss on debt extinguishment 708,000 Loss on debt extinguishment 708,000 Accounts receivable 361,000 698,000 Increases (decreases) in cash caused by changes in operating assets and liabilities:		257,000			
Gain on sale of assets (4,392,000) Loss on debt exitinguishment 708,000 Increases (decreases) in cash caused by changes in operating assets and liabilities: 361,000 698,000 Inventories (975,000) (93,000) Other current assets 69,000 (253,000) Other current assets (10,00,000) 254,000 Deferred revenues, related party (638,000) (24,13,000) Deferred revenues, related party (638,000) (23,07,000) Long term deferred rent (2,000) 180,0000 Net cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities: (25,064,000) (23,877,000) Purchases of property and equipment (500,000) Purchases of property and equipment (500,000) Reak acquired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Proceeds from financing activities: 27,000,000 Principal payments on long-term obligations (22,292,000) (21,0000) Proceeds from fina		(4,892,000)			
Loss on debt extinguishment 708,000 — Increases (decreases) in cash caused by changes in operating assets and liabilities: 361,000 698,000 Accounts receivable 361,000 698,000 Increases (decreases) in cash caused by changes in operating assets and liabilities: 361,000 698,000 Other current assets 69,000 (233,000) Other assets (117,000) 16,000 Accounts payable and accrued expenses (1,080,000) 254,000 Deferred revenues, related party (638,000) (2,413,000) Deferred revenues, related party (638,000) (2,413,000) Icong.term deferred revenues (2,000) (83,000) (2,000) Icong.term deferred revenues (2,000) (23,877,000) (23,877,000) Cash flows from investing activities: P P P Purchases of property and equipment (536,000) Iccrease agreement termination fee (600,000) Uclease agreement termination fee (600,000) Principal payments on long-term obligations (22,292,000) (21,070,000					
Increases (decreases) in cash caused by changes in operating assets and liabilities: 361,000 698,000 Accounts receivable 1075,000) (93,000) Other current assets 68,000 (253,000) Other current assets (117,000) 16,000 Accounts payable and accrued expenses (1,080,000) 254,000 Deferred revenues, related party (633,000) (24,13,000) Deferred revenues, related party (25,064,000) (23,877,000) Net cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities (25,064,000) (23,877,000) Purchases of property and equipment (536,000) (-0,077,000) Porceeds from Puregrafi divestiture 5,000,000 - Cash acquired in purchase of Joint Venture 5,000 - Principial payments on long-term obligations (22,292,000) (21,000) Principial payments on long-term obligations (22,292,000) (21,000) Proceeds from long-term obligations (22,292,000) (21,000) Proceeds from long-term obligations (22,292,000) (21,000) Proceeds from long-term obligations (22,292,000)					
Accounts receivable 361,000 698,000 Inventories (975,000) (935,000) Other current assets 60,000 (253,000) Other assets (11,7000) 16,000 Accounts payable and accrued expenses (11,800,000) 254,000 Deferred revenues, related party (638,000) (2413,000) Long-term deferred rent (2,000) 180,000 Vet cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities: Purchases of property and equipment (536,000) (-1,077,000) Proceeds from Puregraft divestiture 5,000,000 Cash acquired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Cash flows from financing activities: 22,292,000) (21,0000) Principal payments on long-term obligations (22,292,000) (21,0000) Proceeds from long-term obligations (22,292,000) (21,0000) Proceeds from long-term obligations (22,292,000) (21,0000) Proceeds from long-term obligation					
Inventories (93,000) Other current assets (1000) Accounts payable and accrued expenses (1,000) Cash accounts payable and accrued expenses (1,000) Deferred revenues, related party (638,000) Deferred revenues, related party (638,000) Long-term deferred rent (2,000) Net cash used in operating activities (25,064,000) Purchases of property and equipment (536,000) Proceeds from Puregraft divestiture 5,000,000 Droceeds from Puregraft divestiture 5,000 Cash acquired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities (210,000) Cash flows from financing activities: (22,292,000) Net cash provided by (used in) investing activities 3,869,000 Cash flows from financing activities: (1,744,000) Principal payments on long-term obligations (22,022,000) Proceeds from long-term obligations (27,000,000) Proceeds from sale of common stock (11,744,000) Payments on long-term obligations (27,000,000) Proceeds from sale of common stock		361.000	698.000		
Other current assets 69,000 (253,000) Other assets (117,000) 16,000 Accounts payable and accrued expenses (1,080,000) 254,000 Deferred revenues, related party (638,000) (2,413,000) Deferred revenues (1,245,000) (7,000) Long-term deferred rent (2000) 180,000 Net cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities: """"""""""""""""""""""""""""""""""""	Inventories				
Other assets (117,000) 16,000 Accounts payable and accrued expenses (1,080,000) 254,000 Deferred revenues, related party (638,000) (2,413,000) Deferred revenues, related party (12,45,000) (97,000) Long-term deferred rent (2,000) 180,000 Net cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities: (536,000) (23,877,000) Purchases of property and equipment (536,000) (-0,000) Proceeds from Puregraft divestiture 5,000,000 - License agreement termination fee (600,000) - Cash acquired in purchase of Joint Venture 5,000 - Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Principal payments on long-term obligations (22,292,000) (210,000) Proceeds from linancing activities: 27,000,000 - Proceeds from setck options and warrants and stock purchase plan (17,44,000) - Port cash flows from financing activities 3,001,000 4,946,000 Proceeds f					
Accounts payable and accrued expenses (1,080,000) 254,000 Deferred revenues, related party (638,000) (2,413,000) Long-term deferred rent (2,000) 180,000 Net cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities: (25,064,000) (23,877,000) Purchases of property and equipment (536,000) (1,077,000) Proceeds from Puregraft divesiture 5,000,000 Cash acquired in purchase of Joint Venture 5,000 Scash quired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities (22,292,000) (21,077,000) Principal payments on long-term obligations (22,292,000) (21,0000) Proceeds from long-term obligations (22,292,000) (21,0000) Proceeds from long-term obligations (22,292,000) (21,0000) Proceeds from long-term obligations (21,044,000) Payments toward purchase of Joint Venture (11,074,000) Proceeds from sale of common stock (104,000) Proceeds from sale of common stock (184,000) (184,			,		
Deferred revenues, related party(638,000)(2,413,000)Deferred revenues(1,245,000)(2,000)180,000Long-term deferred rent(2,000)180,000Net cash used in operating activities(25,064,000)(23,877,000)Cash flows from investing activities:(536,000)(1,077,000)Purchases of property and equipment(536,000)(1,077,000)Proceeds from Puregraft divestiture5,000,000License agreement termination fee(600,000)Cash acquired in purchase of Joint Venture3,869,000(1,077,000)Net cash provided by (used in) investing activities3,869,000(1,077,000)Cash flows from financing activities:27,000,000Principal payments on long-term obligations(22,292,000)(210,000)Proceeds from long-term obligations(27,000,000)Payments toward purchase of Joint Venture(1,744,000)Proceeds from long-term obligations(27,000,000)Proceeds from sale of common stock(141,000)Proceeds from sale of common stock(141,000)Proceeds from sale of common stock(184,000)(64,000)Cash provided by financing activities5,787,0005,660,000Effect of exchange rate changes on cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000					
Deferred revenues (1,245,000) (97,000) Long-term deferred rent (2,000) 180,000 Net cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities: (536,000) (1,077,000) Proceeds from Puregraft divestiture 5,000,000 License agreement termination fee (600,000) Cash acquired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Cash flows from financing activities: 27,000,000 Principal payments on long-term obligations (22,292,000) (210,000) Proceeds from long-term obligations (27,000,000 Principal payments on long-term obligations (22,292,000) (210,000) Proceeds from exercise of employee stock options and warrants and stock purchase plan (1,474,000) Proceeds from sale of common stock (184,000) (64,000) - Proceeds from sale of common stock (184,000) (64,000) - Reverses in cash and cash equivalents (104,000)					
Long-term deferred rent(2,000)180,000Net cash used in operating activities(25,064,000)(23,877,000)Cash flows from investing activities(536,000)(-Purchases of property and equipment(536,000)-Proceeds from Puregraft divestiture5,000,000-Cash acquired in purchase of Joint Venture(600,000)-Net cash provided by (used in) investing activities3,869,000(1,077,000)Proceeds from financing activities:(22,292,000)(210,000)Proceeds from fong-term obligations(22,292,000)(210,000)Proceeds from exercise of employee stock options and warrants and stock purchase plan147,000-Proceeds from sale of common stock(184,000)(4946,000)Costs af occument stock(184,000)(64,000)Net cash provided by financing activities5,787,0005,660,000Costs from sale of common stock(104,000)-Recease in cash and cash equivalents(104,000)-Net decrease in cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000					
Net cash used in operating activities (25,064,000) (23,877,000) Cash flows from investing activities: (536,000) (1,077,000) Proceeds from Puregraft divestiture 5,000,000 License agreement termination fee (600,000) Cash acquired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Cash flows from financing activities: (22,292,000) (210,000) Principal payments on long-term obligations (22,000) (210,000) Proceeds from long-term obligations (27,000,000) Port cash and cash equivalents and stock purchase plan 147,000) Payments toward purchase of Joint Venture 3,001,000 4,946,000 Costs from sale of common stock (184,000) (64,000) Costs from sale of common stock 5,787,000 5,660,000 Effect of exchange rate changes on cash and cash equivalents (104,000) Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash arguer is a beginning of period 25,717,000 36,922,000					
Cash flows from investing activities: Purchases of property and equipment Proceeds from Puregraft divestiture License agreement termination fee Cash acquired in purchase of Joint Venture Cash acquired in purchase of Joint Venture Net cash provided by (used in) investing activities Principal payments on long-term obligations (22,292,000) Principal payments on long-term obligations (1,744,000) Payments toward purchase of Joint Venture Payments toward purchase of Joint Venture Proceeds from long-term obligations (22,292,000) Proceeds from long-term obligations (11,744,000) Proceeds from seercise of employee stock options and warrants and stock purchase plan Proceeds from sale of common stock Costs from sale of common stock Costs from sale of common stock Cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents (104,000) Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000	Long-term detented tent	(2,000)	100,000		
Purchases of property and equipment $(536,000)$ $(1,077,000)$ Proceeds from Puregraft divestiture $5,000,000$ License agreement termination fee $(600,000)$ Cash acquired in purchase of Joint Venture $5,000$ Net cash provided by (used in) investing activities $3,869,000$ $(1,077,000)$ Cash flows from financing activities: $2,292,000$ $(210,000)$ Principal payments on long-term obligations $(22,292,000)$ $(210,000)$ Proceeds from long-term obligations $(27,000,000)$ Payments toward purchase of Joint Venture $(11,744,000)$ Proceeds from sale of common stock $(1141,000)$ Proceeds from sale of common stock $(184,000)$ $(64,000)$ Net cash provided by financing activities $5,787,000$ $5,660,000$ Costs from sale of common stock $(104,000)$ Net cash provided by financing activities $5,787,000$ $5,660,000$ Costs from sale of common stock $(104,000)$ Net decrease in cash and cash equivalents $(15,512,000)$ $(19,294,000)$ Cash and cash equivalents at beginning of period $25,717,000$ $36,922,000$	Net cash used in operating activities	(25,064,000)	(23,877,000)		
Purchases of property and equipment $(536,000)$ $(1,077,000)$ Proceeds from Puregraft divestiture $5,000,000$ License agreement termination fee $(600,000)$ Cash acquired in purchase of Joint Venture $5,000$ Net cash provided by (used in) investing activities $3,869,000$ $(1,077,000)$ Cash flows from financing activities: $2,292,000$ $(210,000)$ Principal payments on long-term obligations $(22,292,000)$ $(210,000)$ Proceeds from long-term obligations $(27,000,000)$ Payments toward purchase of Joint Venture $(11,744,000)$ Proceeds from sale of common stock $(1141,000)$ Proceeds from sale of common stock $(184,000)$ $(64,000)$ Net cash provided by financing activities $5,787,000$ $5,660,000$ Costs from sale of common stock $(104,000)$ Net cash provided by financing activities $5,787,000$ $5,660,000$ Costs from sale of common stock $(104,000)$ Net decrease in cash and cash equivalents $(15,512,000)$ $(19,294,000)$ Cash and cash equivalents at beginning of period $25,717,000$ $36,922,000$	Cash flows from investing activities:				
Proceeds from Puregraft divestiture 5,000,000 License agreement termination fee (600,000) Cash acquired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Cash flows from financing activities: Principal payments on long-term obligations (22,292,000) (210,000) Proceeds from long-term obligations 27,000,000 Proceeds from long-term obligations (1,744,000) Pebt issuance costs and loan fees (1,744,000) Proceeds from exercise of employee stock options and warrants and stock purchase plan 1447,000 988,000 Proceeds from sale of common stock (184,000) (64,000) Costs from sale of common stock 5,787,000 5,660,000 Net cash provided by financing activities 5,787,000 5,660,000 Effect of exchange rate changes on cash and cash equivalents (104,000) Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000 36,922,000		(536,000)	(1.077.000)		
License agreement termination fee (600,000) Cash acquired in purchase of Joint Venture 5,000 Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Cash flows from financing activities: 27,000,000 Principal payments on long-term obligations (22,292,000) (210,000) Proceeds from long-term obligations 27,000,000 Payments toward purchase of Joint Venture (141,000) Proceeds from sale of common stock 3,8000 70000 98,000 Proceeds from sale of common stock 3,001,000 4,946,000 Net cash provided by financing activities 5,787,000 5,660,000 Net cash provided by financing activities 5,787,000 5,660,000 Net cash provided by financing activities 1104,000) Refer to f exchange rate changes on cash and cash equivalents (104,000) Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000 36,922,000			(1,077,000)		
Cash acquired in purchase of Joint Venture 5,000 — Net cash provided by (used in) investing activities 3,869,000 (1,077,000) Cash flows from financing activities: Principal payments on long-term obligations (22,292,000) (210,000) Proceeds from long-term obligations 27,000,000 — Debt issuance costs and loan fees (1,744,000) — Proceeds from exercise of employee stock options and warrants and stock purchase plan 147,000 988,000 Proceeds from sale of common stock 3,001,000 4,946,000 Costs from sale of common stock (184,000) (64,000) Net cash provided by financing activities 5,787,000 5,660,000 Effect of exchange rate changes on cash and cash equivalents (104,000) — Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000 36,922,000					
Net cash provided by (used in) investing activities3,869,000(1,077,000)Cash flows from financing activities: Principal payments on long-term obligations(22,292,000)(210,000)Proceeds from long-term obligations27,000,000Debt issuance costs and loan fees(1,744,000)Payments toward purchase of Joint Venture(141,000)Proceeds from sale of common stock options and warrants and stock purchase plan147,000988,000Proceeds from sale of common stock(184,000)(64,000)Costs from sale of common stock5,787,0005,660,000Net cash provided by financing activities5,787,0005,660,000Effect of exchange rate changes on cash and cash equivalents(104,000)Net decrease in cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000					
Cash flows from financing activities: Principal payments on long-term obligations (22,292,000) Proceeds from long-term obligations 27,000,000 Debt issuance costs and loan fees (1,744,000) Payments toward purchase of Joint Venture (141,000) Proceeds from exercise of employee stock options and warrants and stock purchase plan 147,000 988,000 Proceeds from sale of common stock 3,001,000 4,946,000 Costs from sale of common stock (184,000) (64,000) Net cash provided by financing activities 5,787,000 5,660,000 Effect of exchange rate changes on cash and cash equivalents (104,000) — Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000 36,922,000		3,000			
Principal payments on long-term obligations(22,292,000)(210,000)Proceeds from long-term obligations27,000,000Debt issuance costs and loan fees(1,744,000)Payments toward purchase of Joint Venture(141,000)Proceeds from exercise of employee stock options and warrants and stock purchase plan147,000988,000Proceeds from sale of common stock(184,000)(64,000)Costs from sale of common stock5,787,0005,660,000Net cash provided by financing activities5,787,000Net decrease in cash and cash equivalents(104,000)Cash and cash equivalents at beginning of period25,717,00036,922,000	Net cash provided by (used in) investing activities	3,869,000	(1,077,000)		
Proceeds from long-term obligations27,000,000Debt issuance costs and loan fees(1,744,000)Payments toward purchase of Joint Venture(141,000)Proceeds from exercise of employee stock options and warrants and stock purchase plan147,000Proceeds from sale of common stock3,001,000Costs from sale of common stock(184,000)Met cash provided by financing activities5,787,000Effect of exchange rate changes on cash and cash equivalents(104,000)Net decrease in cash and cash equivalents(15,512,000)Cash and cash equivalents at beginning of period25,717,00036,922,00036,922,000	Cash flows from financing activities:				
Debt issuance costs and loan fees(1,744,000)—Payments toward purchase of Joint Venture(141,000)—Proceeds from exercise of employee stock options and warrants and stock purchase plan147,000988,000Proceeds from sale of common stock3,001,0004,946,000Costs from sale of common stock(184,000)(64,000)Net cash provided by financing activities5,787,0005,660,000Effect of exchange rate changes on cash and cash equivalents(104,000)—Net decrease in cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000	Principal payments on long-term obligations	(22,292,000)	(210,000)		
Payments toward purchase of Joint Venture(141,000)—Proceeds from exercise of employee stock options and warrants and stock purchase plan147,000988,000Proceeds from sale of common stock3,001,0004,946,000Costs from sale of common stock(184,000)(64,000)Net cash provided by financing activities5,787,0005,660,000Effect of exchange rate changes on cash and cash equivalents(104,000)—Net decrease in cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000	Proceeds from long-term obligations	27,000,000	_		
Payments toward purchase of Joint Venture(141,000)—Proceeds from exercise of employee stock options and warrants and stock purchase plan147,000988,000Proceeds from sale of common stock3,001,0004,946,000Costs from sale of common stock(184,000)(64,000)Net cash provided by financing activities5,787,0005,660,000Effect of exchange rate changes on cash and cash equivalents(104,000)—Net decrease in cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000	Debt issuance costs and loan fees	(1,744,000)	_		
Proceeds from exercise of employee stock options and warrants and stock purchase plan 147,000 988,000 Proceeds from sale of common stock 3,001,000 4,946,000 Costs from sale of common stock (184,000) (64,000) Net cash provided by financing activities 5,787,000 5,660,000 Effect of exchange rate changes on cash and cash equivalents (104,000) — Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000 36,922,000		(141,000)			
Proceeds from sale of common stock 3,001,000 4,946,000 Costs from sale of common stock (184,000) (64,000) Net cash provided by financing activities 5,787,000 5,660,000 Effect of exchange rate changes on cash and cash equivalents (104,000) — Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000 36,922,000		147,000	988,000		
Costs from sale of common stock(184,000)(64,000)Net cash provided by financing activities5,787,0005,660,000Effect of exchange rate changes on cash and cash equivalents(104,000)—Net decrease in cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000					
Net cash provided by financing activities5,787,000Effect of exchange rate changes on cash and cash equivalents(104,000)Net decrease in cash and cash equivalents(15,512,000)Cash and cash equivalents at beginning of period25,717,00036,922,000					
Effect of exchange rate changes on cash and cash equivalents (104,000) — Net decrease in cash and cash equivalents (15,512,000) (19,294,000) Cash and cash equivalents at beginning of period 25,717,000 36,922,000		(,,	(0.,000)		
Net decrease in cash and cash equivalents(15,512,000)(19,294,000)Cash and cash equivalents at beginning of period25,717,00036,922,000	Net cash provided by financing activities	5,787,000	5,660,000		
Cash and cash equivalents at beginning of period 25,717,000 36,922,000	Effect of exchange rate changes on cash and cash equivalents	(104,000)			
Cash and cash equivalents at beginning of period 25,717,000 36,922,000	Net decrease in cash and cash equivalents	(15 512 000)	(19.294.000)		
Cash and cash equivalents at end of period \$ 10,205,000 \$ 17,628,000	Cash and cash equivalents at beginning of period	25,717,000	36,922,000		
	Cash and cash equivalents at end of period	\$ 10,205,000	5 17,628,000		